C-type natriuretic peptide gene therapy
Latest Information Update: 20 Jul 2006
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Coronary artery restenosis
Most Recent Events
- 20 Jul 2006 No development reported - Preclinical for Coronary artery restenosis in Japan (Intracoronary)
- 24 Oct 2002 A preclinical study has been added to the Ischaemic Heart Disease pharmacodynamics section
- 03 May 2000 Preclinical development for Coronary artery restenosis in Japan (Intracoronary)